Replimune Group
REPL
135 hedge funds and large institutions have $1.29B invested in Replimune Group in 2022 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 62 increasing their positions, 24 reducing their positions, and 4 closing their positions.
15,989% more call options, than puts
Call options by funds: $4.34M | Put options by funds: $27K
725% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 4
158% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 24
133% more funds holding in top 10
Funds holding in top 10: 3 → 7 (+4)
83% more capital invested
Capital invested by funds: $704M → $1.29B (+$587M)
27% more funds holding
Funds holding: 106 → 135 (+29)
14.22% more ownership
Funds ownership: 82.66% → 96.88% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$24.7M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$20.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18.6M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$14.2M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$21M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$19.2M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.74M |
| 4 |
AG
Artal Group
Luxembourg
|
-$4.16M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.87M |
REPL Hedge Fund Activity: Q4 2022 in Review
135 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Replimune Group (REPL) for Q4 2022, worth a combined $1.29B — up 83% from $704M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new REPL positions and 4 closed out — a net gain of 29 holders — while 62 added to existing stakes and 24 trimmed.
The largest buyer was Redmile Group, adding an estimated $24.7M. The largest seller was Atlas Venture Life Science Advisors, cutting an estimated $21M.
- 135 institutional investors held Replimune Group (REPL) as of Q4 2022, up from 106 in Q3 2022.
- Funds reported $1.29B of Replimune Group stock for Q4 2022, up 83% quarter-over-quarter.
- 33 funds opened new Replimune Group positions in Q4 2022 and 4 closed out, a net change of +29 holders.
- The largest Replimune Group buyer in Q4 2022 was Redmile Group, an estimated $24.7M added.
- The largest Replimune Group seller in Q4 2022 was Atlas Venture Life Science Advisors, an estimated $21M sold.
Based on aggregated 13F filings for Q4 2022.